ALCON INC

Drug pipeline (55)

Asset	Stage	Revenue	Trials	Status
ALCAINE	approved	—	0	—
BETADINE	approved	—	0	—
BETAXON	approved	—	1	approved
BETOPTIC PILO	approved	—	0	—
BRIMONIDINE TARTRATE; TIMOLOL MALEATE	approved	—	12	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (257)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00767481	phase3	terminated	2008-10-01	2009-02-01	Alcon Research	1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
NCT00643669	phase2	completed	2008-02-01	2008-04-01	Alcon Research	24 Hour IOP Lowering Efficacy of AL-3789
NCT02770248	phase4	completed	2016-05-23	2017-01-14	Alcon Research	24-hr Intraocular Pressure Control With SIMBRINZA ®
NCT02140060	phase2	completed	2014-06-01	2014-11-01	Alcon Research	6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389	phase3	completed	2003-01-01	2004-09-01	Alcon Research	A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

FDA applications (60)

Application

Approved

Type

Applicant

Products

NDA 217370

2025-05-28

NDA

ALCON LABORATORIES INC

NDA 210933

2020-10-26

NDA

ALCON LABORATORIES INC

NDA 208259

2019-03-12

NDA

ALCON LABORATORIES INC

NDA 210565

2018-08-22

NDA

ALCON LABORATORIES INC

NDA 208254

2017-12-18

NDA

ALCON LABORATORIES INC